GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » Gross-Profit-to-Asset %

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Gross-Profit-to-Asset % : 13.22% (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nanjing King-Friend Biochemical Pharmaceutical Co's annualized Gross Profit for the quarter that ended in Mar. 2025 was ¥1,218 Mil. Nanjing King-Friend Biochemical Pharmaceutical Co's average Total Assets over the quarter that ended in Mar. 2025 was ¥9,219 Mil. Therefore, Nanjing King-Friend Biochemical Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 13.22%.


Nanjing King-Friend Biochemical Pharmaceutical Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co Gross-Profit-to-Asset % Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.86 26.24 21.34 19.48 17.81

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.14 19.59 17.35 17.60 13.22

Competitive Comparison of Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset % falls into.


;
;

Nanjing King-Friend Biochemical Pharmaceutical Co Gross-Profit-to-Asset % Calculation

Nanjing King-Friend Biochemical Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=1695.216/( (9524.264+9509.95)/ 2 )
=1695.216/9517.107
=17.81 %

Nanjing King-Friend Biochemical Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=1218.428/( (9509.95+8928.306)/ 2 )
=1218.428/9219.128
=13.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Nanjing King-Friend Biochemical Pharmaceutical Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing King-Friend Biochemical Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Executives
Huang Xi Wei Director
Liu Zu Qing Supervisors
Xie Ju Hua Director
Wu Gui Ping senior management
Tang Yong Qun Director
Qian Xiao Jie senior management

Nanjing King-Friend Biochemical Pharmaceutical Co Headlines

No Headlines